Balyasny Asset Management L.P. Takes Position in Perspective Therapeutics, Inc. (NYSE:CATX)

Balyasny Asset Management L.P. purchased a new position in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 130,914 shares of the company's stock, valued at approximately $418,000. Balyasny Asset Management L.P. owned 0.19% of Perspective Therapeutics at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Affinity Asset Advisors LLC grew its position in shares of Perspective Therapeutics by 160.0% in the fourth quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company's stock valued at $4,147,000 after purchasing an additional 800,000 shares during the last quarter. Walleye Capital LLC lifted its stake in Perspective Therapeutics by 2,526.2% in the 4th quarter. Walleye Capital LLC now owns 475,792 shares of the company's stock valued at $1,518,000 after buying an additional 457,675 shares in the last quarter. Jump Financial LLC acquired a new stake in Perspective Therapeutics during the 4th quarter valued at $688,000. JPMorgan Chase & Co. increased its position in Perspective Therapeutics by 498.3% during the fourth quarter. JPMorgan Chase & Co. now owns 149,045 shares of the company's stock worth $475,000 after buying an additional 124,133 shares in the last quarter. Finally, WealthPlan Investment Management LLC raised its holdings in shares of Perspective Therapeutics by 18.2% in the fourth quarter. WealthPlan Investment Management LLC now owns 401,049 shares of the company's stock worth $1,279,000 after acquiring an additional 61,757 shares during the last quarter. 54.66% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CATX has been the topic of several recent research reports. Truist Financial reduced their price objective on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a report on Tuesday, March 4th. Scotiabank assumed coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $15.00 price target for the company. Brookline Capital Management raised shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Monday, March 10th. Finally, Royal Bank of Canada decreased their target price on shares of Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating on the stock in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $12.50.

Perspective Therapeutics Price Performance

Shares of CATX traded up $0.05 during mid-day trading on Thursday, hitting $2.51. The company had a trading volume of 46,261 shares, compared to its average volume of 1,030,552. Perspective Therapeutics, Inc. has a 1-year low of $1.60 and a 1-year high of $16.70. The business's 50-day simple moving average is $2.25 and its 200-day simple moving average is $3.51.

Insiders Place Their Bets

In other news, CFO Juan Graham acquired 33,333 shares of Perspective Therapeutics stock in a transaction dated Friday, March 28th. The shares were acquired at an average cost of $2.25 per share, with a total value of $74,999.25. Following the purchase, the chief financial officer now directly owns 35,354 shares of the company's stock, valued at approximately $79,546.50. This trade represents a 1,649.33% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert F. Williamson III bought 38,145 shares of the firm's stock in a transaction dated Monday, March 31st. The shares were purchased at an average price of $2.14 per share, with a total value of $81,630.30. Following the acquisition, the director now directly owns 108,982 shares in the company, valued at approximately $233,221.48. This trade represents a 53.85% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 115,696 shares of company stock valued at $256,344 over the last quarter. Company insiders own 3.72% of the company's stock.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.